• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
Drug Products, Labeling, and Packaging
Drug Products, Labeling, and Packaging

... innovative ways to ensure patient access to orphan drug products. This policy supersedes ASHP policy 0715. Rationale The U.S. Orphan Drug Act of 1983 and similar programs in other countries have greatly expanded the number of therapies available to treat rare diseases through the use of financial an ...
File
File

... followed by effect • Antagonist: a drug that interact with a receptor but with no effect • Partial Agonist: a drug that bind to a receptor followed by weak effect ...
n MANUFACTURERS NATIONALASSOCIATION OF PHARMACUT}
n MANUFACTURERS NATIONALASSOCIATION OF PHARMACUT}

... This section represents a significant regulatory change that is in conflict with the USP. According to this section, a manufacturer of a drug substance whose process produces a drug substance with low impurity levels and another manufacturer of the same drug substance with higher impurity levels wil ...
Medication-KSU
Medication-KSU

... MEDICATION King Saud University College of Nursing NUR 122 ...
Medication
Medication

... MEDICATION King Saud University College of Nursing NUR 122 ...
PowerPoint Template
PowerPoint Template

... 1. nonaqueous liquids and solid formulations in which the manufactured drug is the source of the active ingredient, not later than 25% of the time remaining until the product’s expiration date or 6 months, whichever is earlier. 2. nonaqueous liquids and solid formulations in which a USP or National ...
Module Three Pharmacology, Medical and Pharmacy Abbreviations
Module Three Pharmacology, Medical and Pharmacy Abbreviations

... the site of administration and is transported to the blood stream. This occurs orally, rectally, intravenously, topically, or by inhalation. ii. Distribution – This is the process where a drug is delivered to specific organs and tissues via the blood stream to exert its pharmacological effect. iii. ...
Basic-Pharm-161-Presentation-pharmacokinetics1
Basic-Pharm-161-Presentation-pharmacokinetics1

... o More soluble, more rapidly absorbed o Most drugs are Water-sol (most readily absorbed)- and partially lipid soluble  Law of Diffusion- drug molecules pass from an area of high concentration to an area of low concentration – – Concentration of drug on each side ...
What are Predatory Drugs
What are Predatory Drugs

... of National Drug Control Policy, Drug Facts: Club Drugs, May 2002. 3Drug Enforcement Administration, Club Drugs: An Update, September 2001. 4Ibid. 5Ibid. http://mit.edu/cdsa/ 2Office ...
pmcjcr/ pharmacokinetics
pmcjcr/ pharmacokinetics

... • digoxin and digitoxin (plasma or serum) • lithium (serum) • phenytoin (plasma or serum) • theophylline (plasma or serum) • paracetamol and salicylate (overdose) (plasma or serum). ...
Arrest Referral - Scottish Drugs Forum
Arrest Referral - Scottish Drugs Forum

... housing, health and social services ► Real and Practical ► Full Drug Action Team support ► Police commitment across all levels (commander to turnkey) ► Good reporting on progress. ...
NIDA Topics in Brief - Prescription Medications
NIDA Topics in Brief - Prescription Medications

... Among those who abuse prescription drugs, high rates of other riskybehaviors, including abuse of other drugs and alcohol, have also been reported. What is driving this high prevalence? Multiple factors are likelyat work: Misperceptions about their safety. Because these medications are prescribed by ...
ENZYMES
ENZYMES

... The most important enzymes involved in drug interactions are members of the cytochrome P450 (CYP) system that are responsible for many of the phase 1 biotransformations of drugs. These metabolic transformations, such as oxidation, reduction and hydrolysis, produce a molecule that is suitable for con ...
Dr. Schaaf - National Academies
Dr. Schaaf - National Academies

... Diagnosis : M/XDR-TB in children § DR TB is a microbiological diagnosis § In children often difficult (paucibacillary TB): ▫ Confirmed if DR M. tuberculosis strain is isolated ...
Designing concept maps for a precise and objective
Designing concept maps for a precise and objective

... been approved by the French National Medicines Assessment Committee between January 2008 and January 2011. These drugs are presented in Appendix 1. They were randomly selected, but taking into account the total number of new products in each medical discipline and the nature of the pharmaceutical in ...
Sheathless Capillary Electrophoresis
Sheathless Capillary Electrophoresis

... interface for Capillary Electrophoresis-ESI-Mass Spectrometry (CEMS) to the objective of routine screening for drugs and metabolites at sub-therapeutic levels in biofluids. Levels of detection (LOD) for a custom designed Test Mixture were determined for 15 drugs and illustrated for one well known dr ...
priorities for systematic reviews
priorities for systematic reviews

... used in highly specialised units. A drug like chlormethine has highly any indication in cancer therapy any more and is a problematic drug also from the point of toxicity and physical and chemical properties. The Committee mentions that the evidence for deleting asparaginase, chlormethine, dacarbazin ...
Chapter 10 Pharmacology
Chapter 10 Pharmacology

... “The difference between a deadly poison and life saving medicine can be very small; In fact, it is sometimes merely a question of dosage.” Dr. R.E. Schultes ...
(Pharmaceutics) Syllabus
(Pharmaceutics) Syllabus

... inference in estimation of hypothesis testing, statistical procedure in assay development. Development of new analytical method and its validation. In-process quality control tests for various dosage forms including packaging and labeling operations. Brief introduction to general requirements of hea ...
Appendix A: Glossary
Appendix A: Glossary

... post-marketing safety surveillance The monitoring of drug safety by collecting reports of adverse drug effects in the population after a medication has been marketed. prescription medication A medication that can only be prescribed by licensed health professionals who are authorized by law. preventi ...
Course Syllabus-
Course Syllabus-

... Prerequisites: At least a “C” in or concurrent enrollment in NU 207. Texts: Pharmacology and the Nursing Process, 7th ed., Lilley, L., Rainforth Collins, S., and ...
Lesson 2 Medical and Pharmacy Terminology
Lesson 2 Medical and Pharmacy Terminology

... drug products that minimizes microrganism contamination ...
Key to Unit 1 review
Key to Unit 1 review

... c. An active drug is given more effectiveness by the addition of an inactive drug which creates an effect greater than doubling the active drug. d. have opposite effects, so that they cancel out the other's effects. 37. Differentiate between drug tolerance and tachyphylaxis. The longer a person take ...
Antibiotic Prescribing Trends in U.S. Hospitals Raise Flags
Antibiotic Prescribing Trends in U.S. Hospitals Raise Flags

... with uncomplicated bacterial infections, such as urinary tract infections and sinusitis, and that these patients be given alternative treatment options.2 Reducing unnecessary or inappropriate use of fluoroquinolones will help minimize the risks associated with them. New information on prescribing pa ...
Key Points Handouts - Hansen Resource Development Inc
Key Points Handouts - Hansen Resource Development Inc

... Describes what the body does to the drug. It deals with the absorption, distribution, metabolism, and excretion (ADME) of drugs. These factors, coupled with dosage, determine the concentration of a drug at its site of action and, hence, the intensity of its effects as a function of time. ...
< 1 ... 103 104 105 106 107 108 109 110 111 ... 161 >

Orphan drug

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.According to Thomson Reuters in their 2012 publication ""The Economic Power of Orphan Drugs"", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act (ODA) 1983 and similar Acts in other regions of the world and also driven by ""high-profile philanthropic funding."" The period between 2001 to 2011 was the ""most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals."" For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an ""impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs."" By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs, Thomson Reuters.By 2012, ""the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success.""
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report